Humacyte Inc has a consensus price target of $9.88 based on the ratings of 8 analysts. The high is $17 issued by Cowen & Co. on October 29, 2021. The low is $3 issued by Piper Sandler on November 10, 2023. The 3 most-recent analyst ratings were released by BTIG, Cantor Fitzgerald, and Benchmark on July 15, 2024, July 2, 2024, and July 2, 2024, respectively. With an average price target of $11 between BTIG, Cantor Fitzgerald, and Benchmark, there's an implied 32.05% upside for Humacyte Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/15/2024 | Buy Now | 32.05% | BTIG | Ryan Zimmerman | $8 → $11 | Maintains | Buy | Get Alert |
07/02/2024 | Buy Now | -15.97% | Cantor Fitzgerald | Kristen Kluska | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
07/02/2024 | Buy Now | 80.07% | Benchmark | Bruce Jackson | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
05/24/2024 | Buy Now | 80.07% | Benchmark | Bruce Jackson | → $15 | Reiterates | Buy → Buy | Get Alert |
05/13/2024 | Buy Now | 80.07% | Benchmark | Bruce Jackson | → $15 | Reiterates | Buy → Buy | Get Alert |
04/01/2024 | Buy Now | -15.97% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
03/26/2024 | Buy Now | -51.98% | Piper Sandler | Allison Bratzel | $4 → $4 | Maintains | Neutral | Get Alert |
03/25/2024 | Buy Now | 80.07% | Benchmark | Bruce Jackson | → $15 | Reiterates | Buy → Buy | Get Alert |
03/08/2024 | Buy Now | -51.98% | Piper Sandler | Allison Bratzel | $3 → $4 | Maintains | Neutral | Get Alert |
12/27/2023 | Buy Now | 80.07% | Benchmark | Bruce Jackson | $16 → $15 | Maintains | Buy | Get Alert |
12/11/2023 | Buy Now | -27.97% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Initiates | → Buy | Get Alert |
11/10/2023 | Buy Now | -63.99% | Piper Sandler | Matt O'Brien | $3.5 → $3 | Maintains | Neutral | Get Alert |
09/21/2023 | Buy Now | -15.97% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
08/31/2023 | Buy Now | -27.97% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
08/24/2023 | Buy Now | -27.97% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
08/15/2023 | Buy Now | 92.07% | Benchmark | Bruce Jackson | → $16 | Reiterates | Buy → Buy | Get Alert |
06/22/2023 | Buy Now | -27.97% | Cantor Fitzgerald | Kristen Kluska | → $6 | Initiates | → Overweight | Get Alert |
06/12/2023 | Buy Now | 92.07% | Benchmark | Bruce Jackson | → $16 | Reiterates | Buy → Buy | Get Alert |
03/27/2023 | Buy Now | 92.07% | Benchmark | Bruce Jackson | → $16 | Reiterates | → Buy | Get Alert |
07/18/2022 | Buy Now | 20.05% | BTIG | Ryan Zimmerman | $12 → $10 | Maintains | Buy | Get Alert |
10/29/2021 | Buy Now | 104.08% | Cowen & Co. | Joshua Jennings | — | Initiates | → Outperform | Get Alert |
09/24/2021 | Buy Now | 92.07% | Oppenheimer | Suraj Kalia | — | Initiates | → Outperform | Get Alert |
09/22/2021 | Buy Now | 128.09% | BTIG | Ryan Zimmerman | — | Initiates | → Buy | Get Alert |
09/16/2021 | Buy Now | 104.08% | Piper Sandler | Matt O'Brien | — | Initiates | → Overweight | Get Alert |
The latest price target for Humacyte (NASDAQ:HUMA) was reported by BTIG on July 15, 2024. The analyst firm set a price target for $11.00 expecting HUMA to rise to within 12 months (a possible 32.05% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by BTIG, and Humacyte maintained their buy rating.
There is no last upgrade for Humacyte
There is no last downgrade for Humacyte.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a maintained with a price target of $8.00 to $11.00. The current price Humacyte (HUMA) is trading at is $8.33, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.